Cambium Bio raises A$10.85m for Phase 3 dry eye trial
Strategic shareholders committed A$7.1m at a premium to market, and the company secured A$3.75m via non-dilutive R&D Tax Incentive pre-financing, funding Phase 3 of Elate Ocular® for dry eye disease.
Strategic shareholders have committed A$7.1 million at a premium to market, in what the company said is its fourth consecutive equity raise priced at a premium, alongside A$3.75 million of non-dilutive R&D Tax Incentive pre-financing. SYDNEY, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Cambium Bio Limited ASX:CMB (“Cambium Bio” or the…